Press Release

ReVivo Medical Announces Two Appointments to its Board of Advisors

June 29, 2021. Hassan Serhan, Ph.D. and Jacob Einhorn are joining ReVivo Medical's Board of Advisors. "Our current management team is well versed to create new medical devices, develop prototypes, have them tested and conduct clinical trials. Now, as we prepare to start our clinical trial, we wish to make sure that we are positioning ourselves for what comes later: the commercial arena," explains Gary Mittleman, president and CEO. "Thus, we have appointed to our Board of Advisors two individuals with a wealth of new product development experience in the medical orthopaedic and spine device space."

- **Hassan Serhan, Ph.D.** As the former Distinguished Engineering Fellow, Senior Director, Research & Technology, at DePuy Synthes Spine, a J&J company, he was responsible for spine and orthopedics, technology evaluation and development for the entire organization.

- **Jacob Einhorn.** Chief Technology Officer and Co-Founder at Intrinsic Therapeutics, Inc. has 20 plus years of experience developing new technologies mostly focused on spine. He has been responsible for clinical development, commercial marketing, new product development, R&D and regulatory strategy. His career spans Stryker and Pfizer.

About ReVivo Medical, Inc., head-quartered in Albany, New York, is developing implantable medical devices for use by surgeons on patients with spinal pathology. The founders, Darryl DiRisio, MD. Professor of Neurosurgery and A. John Popp Chair, Spinal Surgery at the Albany Medical Center and biomedical engineers Eric Ledet, PhD. and Glenn Sanders, PhD. teamed up with the aim of developing products that improve patient health, facilitate easier surgery and reduce costs in this ever-competitive healthcare arena.

ReVivo Medical expects to begin recruiting for its 50-patient clinical study in late Q2 2021. The trial is scheduled to take place at the Albany Medical Center and the Cleveland Clinic. Study participants will receive ReVivo Medical's next generation design anterior cervical plate and interbody cages used in anterior cervical discectomy and fusion procedures.

“Anterior cervical plates and interbody cages are used in over 400,000 surgical procedures each year representing a multi-billion-dollar market,” says Dr. Darryl DiRisio, Chief Medical Officer. “The primary measure of success in these operations is the rapid achievement of bone fusion which thereby stabilizes the spine.”

“Our cervical plate and cage implants are designed to improve bone formation and achieve a superior rate and quality of fusion as compared to the commonly used devices of today,” explains Eric Ledet, PhD., Chief Science Officer. “Additionally, the designs of our implants incorporate unique features that are intended to make them easier for the surgeon to use.”

None of ReVivo Medical’s devices are currently cleared for use in the United States.

To learn more please visit our website:
ReVivo Medical, Inc. www.revivomedical.com

or YouTube video link: https://www.youtube.com/watch?v=TSRkMt_ycSQ

Contacts:
Gary Mittleman, President and CEO (518) 527-4747 or gmittleman@revivomedical.com
Eric Ledet, PhD., Chief Science Officer (518) 227-0743 eledet@revivomedical.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that are not purely historical regarding ReVivo Medical's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the development, cost, size, intended use and technical specifications of the medical products, the potential impact on outcomes and costs associated with spinal surgeries, and the potential profits to be made by ReVivo Medical pursuant to the successful commercialization of their product(s) and the size of market and market share of products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from ReVivo Medical's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the inability to successfully develop new products and obtain regulatory approval; insufficient outcomes in a clinical trial to achieve clearance; a lack of acceptance in the marketplace by physicians and patients; the inability to manufacture products in commercial quantities at an acceptable cost; possible delays in the company's development programs; the inability of patients or hospitals to receive

reimbursement from third-party payors; inadequate protection from patents to prohibit competitors from making similar devices; and inadequate financial and other resources.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to ReVivo Medical, and ReVivo Medical assumes no obligation to update any such forward-looking statement or reasons why results might differ.